Viewing nowSitagliptin 100 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

MFDS item code 202101405 · Approved 2021.02.18 · Insurance code 657807920
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood glucose levels in patients with type 2 diabetes. It can be administered alone or in combination with metformin when blood glucose control is insufficient with existing diabetes treatments, alongside dietary therapy and exercise. Additionally, it can be used in combination with sulfonylureas, thiazolidinediones, and insulin when blood glucose control is also difficult alone or in combination therapy, enhancing therapeutic efficacy. Therefore, this medication is used to improve blood glucose control in various treatment situations.
This drug is administered once daily at a dose of 100 mg as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.
This medication can cause severe allergic reactions; therefore, if symptoms such as skin rash, difficulty in breathing, or swelling of the face or neck occur after use, discontinue use immediately and seek medical attention. During the course of this medication, severe inflammation of the pancreas (pancreatitis) may occur, so if symptoms such as abdominal pain, vomiting, or fever develop, notify healthcare personnel immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and should also be avoided by those with a severe allergic reaction to this medication or its components. Patients with decreased kidney function may require dosage adjustments and should undergo regular kidney function tests. During treatment, symptoms similar to cold, headache, dyspepsia, diarrhea, etc. may occur, and hypoglycemic symptoms may also appear, so blood glucose levels should be monitored closely. When taken in combination with insulin or other hypoglycemic agents, the risk of hypoglycemia may increase, so dosage adjustments for hypoglycemic agents may be necessary. This medication is not recommended for use during pregnancy and should be avoided while breastfeeding. The safety and efficacy of this medication have not been fully established in individuals under 18 years of age. Elderly patients are at risk of decreased kidney function, so it is important to evaluate kidney function before administration and to check periodically during treatment. In case of overdose, seek medical help immediately for appropriate treatment; some drugs may be removed by hemodialysis. This medication can interact with certain drugs, therefore be sure to inform healthcare personnel if you are taking other medications. Also, if severe joint pain or blistering skin symptoms occur while taking this medication, consult a doctor immediately.
Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin disease, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, severe joint pain accompanied by disability, blistering dermatosis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzyme levels, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is recommended to maintain storage temperature at room temperature between 1 degree and 30 degrees.
Light brown, round, bilaterally convex, film-coated tablet
28 tablets/box [14 tablets/PTPX2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.